3rd Quarter - Report

CHAMBER HILL STRATEGIES for AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL)

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

S.959, the Pharmaceutical Quality, Security and Accountability Act; H.R.3204, the Drug Quality and Security Act

LobbyistCovered position, as disclosed
JENNIFER BELL Legislative Assistant, Rep. John Thune (R-SD)
ADAM ETZION —
MICHAELA SIMS Legislative Counsel, Sen. Bob Kerrey

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 959 (113th), H.R. 3204 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.